成人急性淋巴细胞白血病可测量残留病灶评估和管理的推荐意见：北美专家共识。
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts.
机构信息
The University of Texas MD Anderson Cancer Center, Houston, Texas.
NeoGenomics Laboratories, Inc., Aliso Viejo, California.
出版信息
Am J Hematol. 2019 Feb;94(2):257-265. doi: 10.1002/ajh.25338. Epub 2018 Nov 26.
Abstract
Measurable residual disease (MRD) that persists after initial therapy is a powerful predictor of relapse and survival in acute lymphoblastic leukemia (ALL). However, the optimal use of this information to influence therapeutic decisions is controversial. Herein, we comprehensively review the role of MRD assessment in adults with ALL, including methods to quantify residual leukemia cells during remission, prognostic impact of MRD across ALL subtypes, and available therapeutic approaches to eradicate MRD. This review presents consensus statements and provides an evidence-based framework for practicing hematologists and oncologists to use MRD information to make rational treatment decisions in adult patients with ALL.
摘要
在初始治疗后持续存在的可测量残留疾病（MRD）是急性淋巴细胞白血病（ALL）复发和生存的有力预测指标。然而，将这一信息用于影响治疗决策的最佳方法仍存在争议。本文全面回顾了 MRD 评估在成人 ALL 中的作用，包括在缓解期间定量残留白血病细胞的方法、MRD 在 ALL 各亚型中的预后影响，以及清除 MRD 的可用治疗方法。本综述提出了共识声明，并为血液科医生和肿瘤学家提供了一个循证框架，以便他们在成人 ALL 患者中使用 MRD 信息做出合理的治疗决策。
相似文献
1
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts.
Am J Hematol. 2019 Feb;94(2):257-265. doi: 10.1002/ajh.25338. Epub 2018 Nov 26.
2
How I Diagnose Minimal/Measurable Residual Disease in B Lymphoblastic Leukemia/Lymphoma by Flow Cytometry.
Am J Clin Pathol. 2021 Jan 4;155(1):38-54. doi: 10.1093/ajcp/aqaa242.
3
Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.
J Hematol Oncol. 2019 Oct 23;12(1):108. doi: 10.1186/s13045-019-0790-x.
4
Characteristics and Therapeutic Targeting of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia.
Adv Exp Med Biol. 2018;1100:127-139. doi: 10.1007/978-3-319-97746-1_8.
5
Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.
Surg Pathol Clin. 2019 Sep;12(3):671-686. doi: 10.1016/j.path.2019.03.009. Epub 2019 May 18.
6
Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
Cytometry B Clin Cytom. 2013 Nov-Dec;84(6):359-69. doi: 10.1002/cyto.b.21101. Epub 2013 Jun 26.
7
Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis.
Leukemia. 2012 Dec;26(12):2455-61. doi: 10.1038/leu.2012.123. Epub 2012 May 4.
8
[Dynamically monitoring minimal residual disease in acute leukemia after complete remission by multiparameter flow cytometry and its relation with prognosis].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Apr;21(2):339-42. doi: 10.7534/j.issn.1009-2137.2013.02.016.
9
Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol.
Br J Haematol. 2014 May;165(3):392-401. doi: 10.1111/bjh.12749. Epub 2014 Jan 30.
10
Minimal Residual Disease at First Achievement of Complete Remission Predicts Outcome in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
PLoS One. 2016 Oct 3;11(10):e0163599. doi: 10.1371/journal.pone.0163599. eCollection 2016.
引用本文的文献
1
An Attomolar-Level Biosensor Based on Polypyrrole and TiO@Pt Nanocomposite for Electrochemical Detection of TCF3-PBX1 Oncogene in Acute Lymphoblastic Leukemia.
Sensors (Basel). 2025 Aug 27;25(17):5313. doi: 10.3390/s25175313.
2
The evolving therapeutic revolution in adult acute lymphoblastic leukemia.
Cancer. 2025 May 15;131(10):e35872. doi: 10.1002/cncr.35872.
3
Improved post-transplant outcomes since 2000 for Ph-positive acute lymphoblastic leukemia in first remission: A study from the EBMT Acute Leukemia Working Party.
Hemasphere. 2025 Apr 13;9(4):e70117. doi: 10.1002/hem3.70117. eCollection 2025 Apr.
4
Stem cell transplantation indications for patients with acute leukemia determined by measurable residual disease: what we know and what we do not know.
Blood Sci. 2025 Mar 25;7(2):e00229. doi: 10.1097/BS9.0000000000000229. eCollection 2025 Jun.
5
Blood Plasma Methylated DNA Markers in the Detection of Lymphoma: Discovery, Validation, and Clinical Pilot.
Am J Hematol. 2025 Feb;100(2):218-228. doi: 10.1002/ajh.27533. Epub 2024 Nov 20.
6
[The progress in classification and prognosis evaluation of BCR::ABL1 positive acute lymphoblastic leukemia].
Zhonghua Xue Ye Xue Za Zhi. 2024 Jul 14;45(7):705-710. doi: 10.3760/cma.j.cn121090-20240315-00096.
7
Risk factors for positive post-transplantation measurable residual disease in patients with acute lymphoblastic leukemia.
Chin Med J (Engl). 2025 May 5;138(9):1084-1093. doi: 10.1097/CM9.0000000000003150. Epub 2024 Jul 9.
8
Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently asked questions.
Leukemia. 2024 Sep;38(9):1876-1884. doi: 10.1038/s41375-024-02319-2. Epub 2024 Jun 20.
9
MRD in Philadelphia Chromosome-Positive ALL: Methodologies and Clinical Implications.
Curr Hematol Malig Rep. 2024 Aug;19(4):186-196. doi: 10.1007/s11899-024-00736-9. Epub 2024 Jun 18.
10
Acute lymphoblastic leukaemia.
Nat Rev Dis Primers. 2024 Jun 13;10(1):41. doi: 10.1038/s41572-024-00525-x.
本文引用的文献
1
IKZF1 Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.
J Clin Oncol. 2018 Apr 20;36(12):1240-1249. doi: 10.1200/JCO.2017.74.3617. Epub 2018 Mar 2.
2
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.
N Engl J Med. 2018 Feb 1;378(5):449-459. doi: 10.1056/NEJMoa1709919.
3
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
Blood. 2018 Apr 5;131(14):1522-1531. doi: 10.1182/blood-2017-08-798322. Epub 2018 Jan 22.
4
Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL.
Blood. 2018 Mar 22;131(12):1350-1359. doi: 10.1182/blood-2017-09-806521. Epub 2017 Dec 28.
5
Molecular genetic profile in BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia can further refine outcome prediction in addition to that by end-induction minimal residual disease detection.
Leuk Lymphoma. 2018 Aug;59(8):1899-1904. doi: 10.1080/10428194.2017.1408087. Epub 2017 Dec 3.
6
Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia.
J Clin Oncol. 2018 Jan 1;36(1):34-43. doi: 10.1200/JCO.2017.74.0449. Epub 2017 Nov 13.
7
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Haematologica. 2018 Jan;103(1):107-115. doi: 10.3324/haematol.2017.176917. Epub 2017 Oct 27.
8
Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia.
Blood. 2017 Oct 19;130(16):1832-1844. doi: 10.1182/blood-2017-05-783852. Epub 2017 Aug 8.
9
Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response.
Leuk Lymphoma. 2018 Feb;59(2):363-371. doi: 10.1080/10428194.2017.1344842. Epub 2017 Jul 11.
10
Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis.
JAMA Oncol. 2017 Jul 13;3(7):e170580. doi: 10.1001/jamaoncol.2017.0580.
Zotero 插件